Please login to the form below
human growth hormone
This page shows the latest human growth hormone news and features for those working in and with pharma, biotech and healthcare.
NICE recommends Novartis’ Piqray in combination with Faslodex for advanced breast cancer patients
Around 2, 800 specific breast cancer patients in England and Wales could benefit from the treatment, including postmenopausal women, and men, with hormone receptor positive (HR+), human epidermal growth factor receptor
Latest news
-
Eli Lilly partners with breast cancer advocacy organisations to raise awareness of risk factors
The new initiative is focused on patients diagnosed with the most common subtype of early stage breast cancer – hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-).
-
Gilead’s Trodelvy set for EU approval in breast cancer
Gilead’s Trodelvy (sacituzumab govitecan) has received a positive opinion from the European Medicine Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) as monotherapy for adult patients with ... Gilead’s development programme for
-
FDA approves Eli Lilly’s Verzenio in high risk early breast cancer
with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), node-positive, early breast cancer (EBC) at high risk of recurrence.
-
Strong five-year survival data for Kisqali in breast cancer
The study evaluated Kisqali in combination with letrozole, compared to placebo plus letrozole, in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced or
-
Merck’s Keytruda gains two more approvals in Japan
The Japan Pharmaceuticals and Medical Devices Agency (PMDA) has approved the use of Merck/MSD’s Keytruda in patients with inoperable or recurrent breast cancer that is PD-L1 positive, hormone ... receptor negative and human epidermal growth factor
More from news
Approximately 1 fully matching, plus 27 partially matching documents found.
Latest Intelligence
-
Implementing eHealth innovation
Medications management and eHealth. The reference treatment for patients with GHD is based on recombinant human growth hormone (rhGH) which is identical to the growth hormone produced by the pituitary gland. ... growth hormone deficiency, one in which
-
Pharma deals during December 2014
costs. Pfizer has also signed up to a drug delivery product this month through its $570m licensing deal with Opko Health for a long acting version of human growth hormone (hGH), ... which is currently in phase III trials for the treatment of growth
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Country Manager, Healthcare Communications Agency, Germany
-
Highly competitive salary
- Sanofi halts recruitment for trials assessing MS treatment
- bluebird bio reveals plans to launch two gene therapies
- ONS data reveals significant decrease in COVID-19 antibodies
- AbbVie and Sosei Heptares collaborate in new agreement worth up to $1.2bn
- Eli Lilly to make bebtelovimab commercially available to US states from August
- ONS records a continued fall in UK COVID-19 infections
- Engaging KOLs and Gaining Insights in Pharma's New Normal
- That ‘don’t’ impress me much
- Bristol Myers Squibb and GentiBio in $1.9bn deal to develop IBD therapies
- Novartis’ Pluvicto receives MHRA marketing authorisation to treat advanced prostate cancer
- AstraZeneca and Daiichi Sankyo receive FDA approval for lung cancer drug
- ONS data reveals significant decrease in COVID-19 antibodies
PMHub
Lucid Group Communications Limited
WE’RE ON A MISSION
To transform lives through communication that changes behaviour and improves health outcomes....
Latest intelligence
- The communication challenge of helping he next generation to be healthier
- As the pressure on the health service increases the health of the next generation is vital for everyone. How do we show positive attitudes and change behaviour while future proofing...
- Are we losing sight of what the democratisation of healthcare really looks like?
- We have a core responsibility as healthcare communicators to consistently drive for better inclusion, engagement and compliance. What does the ‘democratisation of healthcare’ really look like?...
- How the Royal Society’s EiR programme can help to drive UK innovation
- ...
